"When I say the drug was life-changing, it was life-changing..for my 4yr old son Lev who is profoundly autistic" - Matt Bielski Defiance CEO (and issuer of ASD) on Yamo Pharma's L1-79, a potential groundbreaking drug which is in phase 2 clinical trial but poised to be first FDA-approved therapy for autism, which 1 in 31 children are diagnosed with in US (incl my youngest son, so this segment def hit home. This is as emotional as ETF IQ gets, but really glad we could have this discussion) w/ @scarletfu @BloombergTV